Drug intelligence / Profile preview

ALM0114

Development stage: Preclinical
Lead developer: Alchemedicine
Modality: Small Molecules
Administration: Ophthalmic

Overview

ALM0114 is a preclinical-stage small molecule therapeutic being developed by Alchemedicine for the treatment of ophthalmic conditions, specifically glaucoma and Fuchs' endothelial corneal dystrophy (FECD). As of 2024, the program is under exclusive evaluation or negotiation with an undisclosed partner. While the specific molecular target and mechanism of action have not been publicly disclosed, the drug is designed to address corneal and ocular hypertensive disorders.

Beyond the preview

Go deeper on ALM0114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM0114.

Explore the full profile